United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $956,195.85. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $367.36 on Friday. The company has a 50-day moving average of $362.70 and a 200 day moving average of $359.94. The firm has a market cap of $16.40 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $214.52 and a 1 year high of $417.82.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics in the 4th quarter worth about $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics in the 3rd quarter worth about $33,000. Dunhill Financial LLC grew its position in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. State of Wyoming purchased a new stake in United Therapeutics during the 4th quarter valued at about $62,000. Finally, Millstone Evans Group LLC purchased a new stake in United Therapeutics during the 4th quarter valued at about $67,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.